Teduglutide for short bowel syndrome in infants


featured image

Teduglutide is in clinical development for infants aged four to twelve months with short bowel syndrome (SBS) who are dependent on parenteral support (PS). SBS is a complex disease that occurs due to the physical loss or the loss of function of a portion of the small and/or large intestine.

Interventions: Teduglutide
Indications: Short bowel syndrome
Therapeutic Areas: Gastroenterology
Year: 2022

Teduglutide is in clinical development for infants aged four to twelve months with short bowel syndrome (SBS) who are dependent on parenteral support (PS). SBS is a complex disease that occurs due to the physical loss or the loss of function of a portion of the small and/or large intestine. Consequently, individuals with SBS often have a reduced ability to absorb nutrients such as fats, carbohydrates (sugars) vitamins, minerals, trace elements and fluids. Although SBS in infants is a very rare condition, SBS can incur significant illness including intestinal failure, cholestasis, sepsis, and death. However, there is a lack of approved treatments for infants with SBS.